Drug
Bibw 2992 Ma2 Day
Bibw 2992 Ma2 Day: highest development phase Phase 2, developed by Boehringer Ingelheim. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| BIBW 2992 MA2 40mg/day NCT00711594 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Bibw 2992 Ma2 Day on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.